Julianne Bruno

Julianne Bruno

Company: CRISPR Therapeutics

Job title: Senior Director


Julianne Bruno currently leads CRISPR Tx’s lead program in hemoglobinopathies focused on beta-thalassemia and sickle cell disease.  In her previous role in New Product Planning at CRISPR, Julianne led the development of commercial launch strategy across both the hemoglobinopathy and I/O portfolio.  Before joining CRISPR, Julianne worked at McKinsey & Company where she was a leader in the biotech practice and served a number of biotechnology companies on a wide range of commercial topics.  Julianne received her MBA from The Wharton School and also holds an A.B. from Princeton University.


Understanding Key Commercial Considerations for a Hemoglobinopathy Gene Therapy Launch 8:45 am

 Exploring specific factors to consider for sickle cell disease and β-thalassemia programs Discussing appropriate market access strategies to ensure patients receive the therapyRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.